Merck Signs Licensing Deal With Santen, Marking Second Deal For Japan’s Top Ophthalmology Maker

Japan's Osaka-based Santen Pharmaceutical April 15 signed a worldwide licensing agreement with Merck for Tapros/Taflotan (tafluprost), a treatment for glaucoma and ocular hypertension